Improvement of Care & Outcome
Obesity is a growing concern among people with type 1 diabetes (PWDs), with weight management becoming increasingly important due to elevated health risks. While automated insulin delivery (AID) systems like the MiniMed™ 780G (MM780G) improve glycemic control and quality of life, their effect on weight is not well understood. Observations of individual weight gain in clinical settings prompted further investigation. Exisiting studies assessing weight changes after start of AID therapy have analyzed the included participants at the group level, without discriminating if participants increased or decreased in weight (expressed as body mass index [BMI]), or remained stable in weight. In this study the primary aim was to assess the ratios of PWDs who increased or who decreased/remained stable in weight after starting AID therapy. Secondary aims were the analysis of possible associations of each of these weight change groups with clinical parameters and AID system parameters.
This retrospective cohort study included 496 PWDs (n=210 aged <21 years; n=286 aged ≥21 years) with at least one year of diabetes duration who began MM780G AID at Diabeter from April 2022 onward. BMI (for adults) and BMI z-scores (for those under 21) were analyzed at baseline and 3–12 months after starting AID. Logistic regression was used to identify risk factors for BMI increase.
Key findings:
Over half of participants experienced a BMI increase post-AID: 66% in youth, 52% in adults.
HbA1c was the only statistically significant predictor of weight change: less improvement or an increase in HbA1c was associated with a lower risk of weight gain.
No other clinical, glycemic, or AID system parameters showed a significant association with BMI changes.
Concluding, the authors state
Please click here for the poster.
Friends of Diabeter
Diabeter.nl